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Abstract
Objective: After 9/11/2001, some Fire Department of New York (FDNY) workers had excessive lung function decline. We
hypothesized that early serum matrix metalloproteinases (MMP) expression predicts World Trade Center-Lung Injury (WTC-
LI) years later.
Methods: This is a nested case-control analysis of never-smoking male firefighters with normal pre-exposure Forced
Expiratory Volume in one second (FEV1) who had serum drawn up to 155 days post 9/11/2001. Serum MMP-1, 2,3,7,8, 9, 12
and 13 were measured. Cases of WTC-LI (N = 70) were defined as having an FEV1 one standard deviation below the mean
(FEV1#77%) at subspecialty pulmonary evaluation (SPE) which was performed 32 months (IQR 21–53) post-9/11. Controls
(N = 123) were randomly selected. We modeled MMP’s ability as a predictor of cases status with logistic regression adjusted
for time to blood draw, exposure intensity, weight gain and pre-9/11 FEV1.
Results: Each log-increase in MMP-3 and MMP-12 showed reduced odds of developing WTC-LI by 73% and 54%
respectively. MMP-3 and MMP-12 consistently clustered together in cases, controls, and the cohort. Increasing time to blood
draw significantly and independently increased the risk of WTC-LI.
Conclusions: Elevated serum levels of MMP-3 and MMP-12 reduce the risk of developing WTC-LI. At any level of MMP-3 or
12, increased time to blood draw is associated with a diminished protective effect.
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Introduction
During the events of September 11th, 2001, the collapse of the
World Trade Center (WTC) pulverized much of the building’s
glass and metal structure and released an estimated 10 million tons
of particulate matter (WTC-PM).[1–4] The bulk particulates were
composed of cement, carbon, cellulose, and several fiber types
including mineral wool, fiberglass and asbestos.[3,4] WTC-PM
was collected, sieved, aerosolized, and was found to range in size
from PM2.5 to PM53.[4] The elemental analysis showed that
WTC-PM was composed of high levels of calcium and sulfur
(mostly in the form of sulfate) and it was found to be highly
alkaline; pH 9–11.[4] Furthermore, induced sputum of firefighters
up to 9 months after the event contained PM2.5–53.[5] Finally,
biomass exposure is a major cause of lung function loss worldwide.
In addition military cohorts exposed to products of combustion
and PM due to close proximity to burn pits provide further insight
into the negative health effects PM exposure. [6]
Approximately 92% of the exposed rescue workers were
subsequently enrolled in the Fire Department of New York-World
Trade Center-Medical Monitoring and Treatment Program.[7]
Serum samples and spirometry were obtained within six months of
exposure at medical monitoring entry (MME). Despite high levels
of exposure the FDNY rescue worker cohort had a very
heterogeneous response in regards to their lung function.[8–10]
Most stabilized, a subset of rescue workers recovered lung function
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while others progressed and their FEV1 declined to less than their
lower limit of normal (LLN). We have previously defined the
persistent loss of FEV1 to less than LLN in this FDNY exposed
population as World Trade Center Lung Injury (WTC-LI).[10–
13] Workers with this progressive disease had bronchial wall
thickening and air trapping on computed tomography (CT),
suggesting airway injury as the predominant lung pathology.[14]
Lower Manhattan residents with WTC exposure have similar
findings.[8,12,14–21] This suggests that airway disease is the most
common manifestation of WTC-LI.
We have previously investigated serum inflammatory, metabolic
syndrome and cardiovascular biomarkers and found them to be
predictors of FEV1 decline and WTC-LI.[11,13,22,23] More
specifically, we found that myeloperoxidase (MPO) and soluble
vascular cell adhesion molecule (sVCAM) can predict recovery
from the original injury.[24] These results demonstrate that patho-
physiological processes in the lung caused by dust and smoke
exposure are reflected by biologically active protein expression in
serum.
The role of proteases has been studied in the setting of many
diseases including cancer, coronary disease, chronic obstructive
pulmonary disease (COPD), and cigarette-induced chronic lung
diseases.[25–29] Increased protease activity is a component of
many diseases, including cigarette-induced chronic lung disease
and other causes of accelerated lung function decline.[25–28] Of
the known proteases, matrix metalloproteinases (MMPs) have
been of particular interest in their role in lung remodeling, and
have been found to be central to the pathogenesis of airway disease
such as COPD. MMPs are a family of Zn2+-dependent proteases
that can catabolize and degrade the extracellular matrix. Many
are known intermediates of each other, and their levels are affected
by environmental factors such as hypoxia, inflammation and
oxidative stress. The utility of MMPs as biomarkers of lung disease
severity and prognostic indicators are of key interest in many
studies.[30] Genetic association studies with MMPs demonstrate a
strong association with lung disease.[25,31,32] MMP-9 has been
studied in induced sputum of WTC-dust-exposed firefighters, and
was found to be related to the time spent during recovery efforts at
the WTC site.[5] MMP-9 has also been used to predict lung
function decline in the setting of a1-antitrypsin deficiency.[33]
However, the overall importance of the proteases in the
development and modulation of lung disease needs further
study.[34–37]
This study investigates the levels of MMPs present in serum
after exposure to WTC dust in rescue workers as potential
systemic biomarkers predicting susceptibility to WTC-LI. It tests
the hypothesis that proteases present within three months of 9/11/
2001 can predict airway injury years later.
Methods
Study participants
This study was approved by both Montefiore Medical Center
and New York University IRB. All subjects signed informed
Institutional Review Board-approved consent at the time of
enrollment allowing analysis of their information and samples for
research (Montefiore Medical Center; #07-09-320 and New York
University; #11-00439). De-identified data devoid of sensitive
information acquired through WTC National Institute of Occu-
pational Safety and Health (NIOSH) funding is available to health
researchers and others in accordance with the Zadroga Act and in
full compliance with the Centers for Disease Control and
Prevention (CDC) and the Agency for Toxic Substances and
Disease Registry (ATSDR) Policy on Releasing and Sharing Data
by request to the WTC Health Program directors.
Prior to 9/11, all subjects had spirometry as part of an annual
physical. At medical monitoring entry (MME), serum samples and
the first post-9/11 spirometry were obtained (Portascreen
Spirometry; S&M Instruments). The population was evaluated
and monitored, and N = 13,234 symptomatic firefighters were
referred to subspecialty pulmonary evaluation (SPE) if they
became symptomatic.[10] Between 10/1/2001 and 3/10/2008,
N = 1720/13,234 presented to a single center for SPE that
included methacholine challenge, diffusing capacity of the lung for
carbon monoxide (DLCO), bronchodilator response (Jaeger
Masterscreen, Viasys Healthcare) and chest CT. Exposure
intensity was defined as high if firefighters reported arrival to the
site the morning of 9/11, and intermediate if they arrived in the
afternoon of 9/11 or on 9/12.
Study design
Similar to previous studies a nested case-control design was used
to measure the association of serum analytes with case status.
[11,13,23,38] Utilizing a cohort control is logistically efficient and
cost-effective for biomarker studies because it samples a control
population that approximates the larger cohort.[11,13,23,38,39]
The study design is also advantageous because it minimizes batch-
bias and freeze-thaw problems associated with biomarker discov-
ery.[38]
Subjects were included in the study if they were never-smoking
male firefighters who had reliable National Health and Nutrition
Examination Survey (NHANES) normative data for predicted
FEV1, post-9/11 FDNY PFTs within 200 days of 9/11, and pre-
9/11 FEV1 .75% pred (n = 801 (47%) out of 1720). [10,12,24]
Those with the most abnormal FEV1% at SPE were identified as
cases of WTC-LI. Cases (n = 100) of WTC-LI were defined as
being within one standard deviation of the lowest FEV1% pred of
the cohort at the time of SPE. The cohort control (N = 171) was
randomly selected from the baseline cohort after stratification on
BMI and FEV1 at MME. Controls (n = 153/171) met inclusion
criteria. Serum was available for the final cohort of n = 123/153
cohort controls and n = 70/100 cases.
Serum biomarker assays
Blood drawn at MME was allowed to stand for 1 hour at room
temperature, and then centrifuged at 1,800g for 10 minutes.
Serum was stored at 280uC (Bio-Reference Laboratories, Inc.
Elmwood Park, NJ), thawed once at 4uC, and assayed using MMP
panel (Procarta/Affymetrix), which had a detection range of 2.44–
40,000 ng/mL. Panels were read on Luminex 200-IS (Luminex
Corporation, Austin, TX) and analyzed with MasterPlexQT
software (Ver. 1.2; MiraiBio, Inc., San Diego, CA). MMP values
were internally validated using manufacturer controls and
standards of known concentrations. Each plate contained a 1:2
ratio of cases to controls to control for batch artifact.
Statistical analysis
We tested normality using the Shapiro-Wilk test and Q-Q plots.
We used Mann–Whitney U test for between group comparisons,
as appropriate. Pearson’s Chi-squared test was used for inferences
on proportions.
Odds ratios were calculated by multivariable logistic regression
using case definition as the outcome variable. Since biomarker
levels were skewed, values were log-transformed and included as
continuous covariates in the model. The Hosmer-Lemeshow
goodness-of-fit test was used to assess the calibration of the model.
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The model discrimination was quantified using the receiver
operating characteristic (ROC) area under the curve (AUC).
Hierarchical clustering was performed using Cluster 3.0 (Ver.
1.47, Michael Eisen: Stanford University; Michiel de Hoon:
University of Tokyo) and Java Treeview (Ver.1.1, Sal-
danha).[40,41] Data was adjusted by log-transformation and
centered on the median.MMP serum levels were clustered by
average linkage using Spearman’s Rank Correlation as the
similarity metric.
Data are expressed as median (interquartile range, IQR) or
Odds Ratio (95% confidence interval), unless otherwise stated. A
two sided p value less than 0.05 was considered significant.
Database management and analyses were performed using SPSS




Derivation of the baseline cohort, cases and controls are
described in Figure 1. N = 123 controls were compared N = 70/
100 cases. Cases and controls were not significantly different in
exposure intensity, time to MME or SPE, BMI at MME, years of
service, or age [Table 1]. However, BMI at SPE and change in
BMI between MME and SPE showed that cases had significantly
increased BMI compared to controls at the later time point.
Median time between 9/11/2001 and SPE for the baseline cohort
was 34 months (IQR range for all groups 25–57).There was no
significant difference in time to MME or SPE for controls and
cases [Table 1].
Longitudinal lung function in cases and controls
Three sequential pulmonary functions tests (PFT) were
performed on this cohort; prior to exposure (Pre-9/11), at
MME, and at SPE [Figure 2] [Table 2].
Although cases had lower pre-9/11 FEV1 (88%) than the
controls (104%), all FDNY workers had normal FEV1 by design.
The controls and cases suffered similar decline of FEV1 in the
interval from pre-9/11 to MME (11% for the controls and cases).
Importantly, controls regained some FEV1 between MME and
SPE, whereas cases continued to lose lung function over this
interval.
Cases had more decline in FEV1/FVC ratio between MME and
SPE (0.81 to 0.71) than controls (0.84 to 0.77) [Table 2]. Evidence
of airway reactivitytracked with the magnitude of changes in
FEV1/FVC ratio. The median bronchodilator response in cases
was 15%, while FEV1 increased only 5% in controls (p,0.001).
Using a 12% FEV1 increase post-bronchodilator as a threshold,
65% of the cases had bronchodilator response compared to only
22% in controls. Similarly, the methacholine slope was at least 4-
fold higher in cases compared to controls. Using a 20% decrease in
FEV1 at the 10 mg/ml methacholine dose as a threshold
(PC20#10 mg/mL, a slope of 0.3125% FEV1 decline/mg of
methacholine), 50% of the cases had airway reactivity compared
to 19% in controls. There was no difference in RV% Predicted.
Cases and controls were significantly different in Total lung
capacity, DLCO, alveolar ventilation (VA) and DLCO/VA
[Table 2]. We used CT imaging to investigate if cases and
controls had different radiographic measures of lung injury. There
was no difference in nodularity, air trapping, or bronchial wall
thickening. Interestingly, the cohort had high prevalence of each
of these radiographic abnormalities.
Serum MMPs
MMP-1,3,8 and 12 were significantly lower in cases that would
progress to WTC-LI than controls who would subsequently
recover some of the lung function lost after WTC exposure. There
was no difference in MMP-2,7,9 and 13 expression in cases and
control [Table 3].
Hierarchical clustering of serum biomarkers tested coordinate
expression of the MMPs [Figure 3]. Clustering the MMPs in the
entire study cohort formed two distinct clusters. The MMPs (1, 3,
8, 12) that were significantly lower in the cases when compared to
controls clustered together. MMP-3 and MMP-12 clustered in the
entire study cohort [Figure 3] and in the cases and controls when
there MMPs were clustered separately, data not shown.
Predictive risk models
We then tested if the MMPs that were different between cases
and controls predicted future lung function with logistic regression.
All MMP levels remained as continuous variables and were log-
transformed to approximate a normal distribution [Table 4].[38]
Covariates in the adjusted models are days to blood draw (9/11 to
MME), change in BMI between blood draw and case definition
(MME to SPE), WTC exposure intensity, and pre-9/11 FEV1%
predicted.
Four models were developed using case definition as the outcome
variable, and assessed for quality using ROC analysis and Hosmer-
Lemeshow goodness of fit statistic. MMP-8 was not a significant
predictor of lung function after adjustments. Although MMP-1,
MMP-3, and MMP-12 demonstrated significant predictive ability,
MMP-1 was discounted from further analysis because it failed
Hosmer-Lemeshow goodness of fit test. Time to serum draw was
also a significant covariate for MMP-3 and MMP-12; every day
post-exposure increased the odds of developing WTC-LI by 1.4%
Figure 1. Study Design. Derivation of Study Cohort from N = 1720
symptomatic FDNY firefighters who presented for subspecialty
pulmonary testing. Serum available and inclusion criteria met for
N = 70/100 cases and N = 123/153 controls.
doi:10.1371/journal.pone.0076099.g001
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and 1.3% respectively. The odds ratios for MMP-3 and MMP-12
were 0.267 and 0.462 respectively, indicating a protective function
of elevated levels of the proteases. MMP-3 and MMP-12
demonstrated excellent predictive ability with AUC of 0.832 and
0.818 respectively. The MMP-12 and MMP-3 models have a
sensitivity of 58.6% and specificity of 86.2%.
The effect of time to blood draw and MMP level of the
probability of developing WTC-LI
To better understand the effect of time on the association
between serum MMP level and WTC-LI, we utilized a contour
plot [Figure 4]. The chance of developing WTC-LI is shown as a
probability isopleth. MMP-3 and MMP-12 both show with
increasing serum levels, probability of WTC-LI is decreased.
Conversely, increasing time to blood draw increased the proba-
bility of WTC-LI. Specifically, as the level of MMP-3 increased
from 2-4.5 Log10 pg/mL, the probability of WTC-LI decreased
from 90% to 20% [Figure 4A]. As the serum level of MMP-12
increased from 1–2.5 Log10 pg/mL, the probability of developing
WTC-LI ranged from 70% to 20% respectively [Figure 4B]. As
time to blood draw increased, the probability of developing WTC-
LI ranged from 70–90% in the MMP-3 model and from 40–70%
for the MMP-12 model.
Discussion
We report that early elevated expression of MMP-3 and MMP-
12 in serum within 200 days after WTC exposure predicts
protected lung function over the subsequent seven years (between
2001–2008). We found that MMP-3 and MMP-12 levels of the
cohort were comparable to other published patient populations,
including healthy controls and patient cohorts with emphysema or
rheumatoid arthritis.[30,42] MMP-3 was found to be more
protective than MMP-12 with an odds ratio of 0.267 compared
to 0.462. Both biomarker models displayed robust predictive
ability by logistic regression with AUC.0.8. Presenting later to
MME and blood draw predicted higher probability of developing
WTC-LI. As time to blood draw increased, the probability of
developing WTC-LI ranged from 70–90% in the MMP-3 model
and from 40–70% for the MMP-12 model.
This cohort provides a unique opportunity identify biomarkers
of susceptibility to dust induced lung injury. First, FEV1 was
measured prior to exposure. Second, after the WTC collapse
produced a massive acute dust exposure, serum was drawn early
during the evolution process to disease. Longitudinal FEV1
measurements allowed us to define case status years after the
serum was drawn. The cohort is also large enough to study only
never-smokers, eliminating a major confounder of reduced FEV1.
The development of FEV1 loss in obstructive lung disease is a
multifactorial process. MMPs are central in the disease pathogen-
esis of obstructive lung disease, and are thus of interest in this
population. MMPs are involved in parenchymal destruction and
lung remodeling, and their quantification allows us to start to
understand their role in the development of FEV1 loss in this
WTC exposed population. Furthermore, they are involved in
separate pathways of disease attenuation than those of inflamma-
tion, cardiovascular disease, and metabolic syndrome that were
the focus of our prior work.
Cases and controls differed in several ways that impacted future
analyses. Incident cases gained significantly more weight than
controls by the time of SPE. BMI is a known cause of decreased
lung function, and is thus a possible confounder. Because our case
Table 1. Demographics of Cohort.
Date/Event Baseline Cohort Susceptible Cases Sub-Cohort Controls p
N 801 70 123
WTC Exposure, N(%) High 197(25%) 18(26%) 21(17%) 0.151
Intermediate 604(75.4%) 52(74%) 102(83%)
9/11 to PFT, Months* MME 2.7(2–4) 2.7(2–4) 2.5(2–3) 0.145
SPE 33.8(25–57) 32.6(21–53) 35.5(26–55) 0.327
BMI, kg/m2* MME 28.0(26–30) 29.0(27–31) 28.0(26–31) 0.106
SPE 28.9(27–31) 29.6(27–34) 29.0(27–31) 0.018
Change 0.8(–0.1–1.8) 1.1(0–2.3) 0.6(–0.4–1.7) 0.003
Years of Service* 9/11/01 13(7–19) 15(8–18) 14(7–18) 0.907
Age* 9/11/01 40(36–45) 40(36–45) 42(37–46) 0.764
*Median (IQR).
WTC, World Trade Center; MME, Medical Monitoring Exam; SPE, Subspecialty Pulmonary Exam; PFT, Pulmonary Function Test; BMI, Body Mass Index.
doi:10.1371/journal.pone.0076099.t001
Figure 2. FEV1% Predicted based on NHANES of Serial PFTs of
Cases and Controls. Median and IQR are represented by box plots,
with median drawn in the middle of the box. The extremes of the error
bars (whiskers) represent 10–90% percentile.
doi:10.1371/journal.pone.0076099.g002
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definition of WTC-LI relies on FEV1 at SPE, it is heavily impacted
by pre-9/11 FEV1 and BMI at SPE, which are both significantly
different between cases and controls prior to model building. For
this reason, we adjust for pre-9/11 FEV1 and change in BMI (as a
measure of weight gain) as confounders in the logistic regression
model. The change in BMI in the logistic regression is simply used
as a marker of weight gain. The model remains robust whether the
weight gain is measured as change in BMI or BMI at SPE.
Cases and controls suffered similar acute reductions in FEV1
from pre-9/11 to MME. This is consistent with the similar WTC
exposure intensities in both case definitions. However, controls
had higher pre-9/11 FEV1 than susceptible cases (102 vs 88%).
The differences in pre-9/11 FEV1 could reflect predisposition to
lung injury after non-tobacco smoke exposure during the
population’s 18 years of service in fighting fires. This is suggested
by continued deterioration of cases in FEV1 compared to the
relative recovery of controls years after the acute WTC exposure.
Because cases were defined by a threshold of FEV1 of ,77% at
SPE, those with pre-9/11 FEV1 close to threshold values were
more likely to meet case definition. Cases also had markedly
diminished airway function across multiple measures after
exposure, including FEV1, lower FEV1/FVC ratio, more bron-
chodilator response, and steeper methacholine response slope.
We observe that increased MMP-3 and 12 expression reduces
the odds of subsequent lung injury. Also, the time to medical
monitoring enrollment and serum draw post-exposure was an
independent predictor of lung injury. Those who had serum
Table 2. Longitudinal Lung Function Assessment of Cohort.
Time Variable Cases N Controls N p
Pre-9/11* FEV1% 88(81–96) 70 104(92–113) 123 ,0.001
FEV1/FVC 81.7(78–86) 70 84.9(81–88) 123 0.001
MME* FEV1% 78(71–89) 70 93(84–99) 123 ,0.001
FEV1/FVC 81.4(76–86) 70 83.8(80–87) 123 0.016
SPE FEV1%* 72(66–75) 70 96(88–104) 123 ,0.001
FEV1/FVC* 71.1(65–77) 70 77.1(73–81) 123 ,0.001
BDR*% 15(7–29) 46 5(2–8) 46 ,0.001
BDR$12%, (N,%) 30(65) 46 10(22) 46 ,0.001
MCT slope* 0.24(0.06–1.78) 34 0.05(0.03–0.11) 102 0.001
PC20#10 mg/mL, (N,%) 17(50) 34 19(19) 102 ,0.001
TLC%* 96(83–106) 47 103(98–109) 53 0.002
RV,% Pred* 130(109–157) 47 123(111–140) 53 0.525
DLCO%* 96(85–107) 46 107(101–116) 52 ,0.001
VA%* 83(75–89) 35 94(87–101) 43 ,0.001
DLCO/VA* 122(113–134) 36 117(105–122) 40 0.038
Nodule, (N,%) 18(45) 40 25(39) 64 0.550
Air Trapping, (N,%) 22(55) 40 27(42) 64 0.203
BWT, (N,%) 13(33) 40 23(36) 64 0.833
*Median (IQR).
FEV1, Forced Expiratory Volume in one second; FVC, Forced Vital capacity; BDR, Bronchodilator Response; MCT, Methacholine Challenge Testing; PC20, Provocative
concentration of methacholine that results in a 20% drop in FEV1; TLC, Total Lung Capacity; RV, Residual Volume; DLco, Diffusing Capacity of the Lung for Carbon
Monoxide; VA, Alveolar Ventilation; BWT, Bronchial Wall Thickening.
doi:10.1371/journal.pone.0076099.t002
Table 3. Serum Biomarkers.
Analyte Cases Controls p
pg/mL N = 70 N = 123
MMP-1* 387(116–864) 775(296–1368) 0.001
MMP-2 2840(1281–5130) 3020(1815–4640) 0.268
MMP-3* 3194(1962–7542) 7653(3320–13765) ,0.001
MMP-7 293(67–396) 222(96–320) 0.382
MMP-8* 2(2–20) 2(2–174) 0.030
MMP-9 25610(12222–74000) 23490(11196–47084) 0.548
MMP-12* 35(7–218) 66(22–313) 0.008
MMP-13 58(9–109) 75(3–141) 0.355
*p,0.05; All values shown as median (IQR).
doi:10.1371/journal.pone.0076099.t003
Figure 3. Hierarchical Clustering of Serum MMPs. Clustering of
MMPs in the cohort, N = 193 showed that MMP3 and MMP-12 clustered
together.
doi:10.1371/journal.pone.0076099.g003
Early MMP-3 and 12 Elevation Protects from WTC-LI
PLOS ONE | www.plosone.org 5 October 2013 | Volume 8 | Issue 10 | e76099
obtained two months post-9/11 (early presenters) had lower risk of
lung injury than those who had serum obtained four months post-
9/11 (late presenters). This result could be due to selection bias
with individuals entering medical monitoring later at a more
advanced stage of disease. Alternately, delay in early interventional
treatment for those who enrolled in medical monitoring later may
have inhibited their ability to recover from the exposure. We
investigated this possibility, but did not find differences between
early and late presenters in known confounders such as exposure
intensity or pre-9/11 FEV1. There was a significant increase in
BMI in the late presenters, but the effect of time did not change
with BMI as a covariate in the logistic models. Time to serum
draw was not a significant covariate with all other serum
biomarkers of risk or protection that we have reported.[11,13,23]
This suggests that the predictive character of MMP expression
over time is distinct from other biomarkers of metabolic syndrome,
vascular injury or inflammation. Another possible interpretation of
the effect of time is early elevation of MMP reflects normal
healing, while persistent MMP elevation occurs with non-resolving
inflammation. Since we do not have serial serum samples from
each individual, we are unable to determine if the association of
time to serum draw post-9/11 with risk of lung injury is due to
selection bias or reflects underlying biology.
The protective role of MMP-12, also known as macrophage
elastase, in this cohort was surprising since most studies on patients
with established lung disease demonstrate elevated MMP-12 as a
biomarker of disease severity in COPD patients.[25] Nevertheless,
there exists murine data for potential protective roles of MMP-12
in the setting of non-small cell lung cancer.[43] The data is
consistent with the hypothesis that after injury, elevated MMP-3
and MMP-12 reduce odds of developing WTC-LI. In this study,
MMP-12 was assayed soon after injury, during the period of
disease evolution, but years before disease was diagnosed. This
makes reverse causation unlikely. It is possible that when
irreversible pulmonary disease is established, increased MMP-12
is a consequence of disease severity and not its cause. Thus, MMPs
would be elevated in more advanced disease due to induction of an
infective or counter-productive repair response.
This is the first paper that describes a protective function of
elevated MMP-3, stromelysin-1, in humans. This novel correlation
needs to be shown in other lung injury cohorts prior to
investigating the relationship of progressive injury pathways and
MMP-3 expression. MMP-3 has been shown to be protective in
murine models of atherosclerosis.[29] Murine models of intestinal
sepsis also showed that deficiency in MMP-3 delayed clearance of
bacteria and impaired migration of CD4+T-cells.[29]
This nested case control study has several limitations. The
cohort was narrowly defined, reducing generalizability of these
results. Specifically, the vast majority of FDNY workers were
exposed at the time of the WTC destruction. The few unexposed
workers were markedly less healthy than the exposed workers pre-
9/11 and most were not on active duty at the time of the event.
Therefore, all the study participants were highly exposed to WTC
dust and products of combustion. Since there is no unexposed
control group with comparable lung function, years of service, age,
racial background and serum available it is therefore not feasible
Table 4. Models of Susceptibility to Lung Injury.*
Model OR (95% CI) AUC HL
MMP-1 0.476 (0.261–0.866) 0.819 (0.755–0.882) 0.034
Time to Serum 1.013 (1.000–1.027)
MMP-3 0.267 (0.121–0.589) 0.832 (0.771–0.893) 0.182
Time to Serum 1.014 (1.000–1.027)
MMP-8 0.675 (0.410–1.111) 0.810 (0.745–0.874) 0.075
Time to Serum 1.010 (0.997–1.024)
MMP-12 0.462 (0.260–0.821) 0.818 (0.755–0.881) 0.506
Time to Serum 1.013(1.000–1.027)
*Each Model Includes: DBMI between MME and SPE, Exposure Group, Pre-9/11
FEV1% Predicted, Time to MME (days) and MMP (Log10 pg/mL).
OR, Odds Ratio; CI, Confidence Interval; AUC, Area Under the Curve; HL, Hosmer
Lemeshow.
doi:10.1371/journal.pone.0076099.t004
Figure 4. Probability of Developing WTC-LI. Contour Plots express probability isopleths for the development of WTC-LI with all other covariates
held constant. When either MMP-3 (A) or MMP-12 (B) increases, the probability of lung injury decreases. As time to blood draw increases, the
probability of lung Injury increases.
doi:10.1371/journal.pone.0076099.g004
Early MMP-3 and 12 Elevation Protects from WTC-LI
PLOS ONE | www.plosone.org 6 October 2013 | Volume 8 | Issue 10 | e76099
to construct an unexposed control. Also, using FEV1 to define case
status may produce misclassification of disease. However, the
authors maintain that using FEV1 is the simplest, most robust, and
best validated single measure of airway injury in an obstructed
cohort. Since the design reduced the potential for selection bias,
misclassification of disease is non-differential. The reported
associations therefore likely underestimate the true strength of
association between the serum biomarkers and subsequent FEV1.
Although the serum biomarkers are expressed years before the
disease is defined, the results are correlations and do not imply
causation. This restricts our ability to assess the impact of WTC
exposure to the observed biomarker disease relationship. Bio-
marker associations with lung injury must also be investigated in
independent cohorts.
WTC exposure impacted multiple distinct injury and repair
pathways. One interpretation of the findings is that biomarkers
that reduce the risk of WTC-LI reflect effective repair after an
acute dust induced lung injury. We report that elevated MMP-3
and MMP-12 are associated with a reduction in the odds of
developing WTC-LI years later. Finally, we show that time to
serum sample acquisition is independently associated with the
probability of lung injury and highlights the utility of serum
sampling efforts continuing for some time. We will investigate in
future studies about the relationship between genetic polymor-
phisms that may improve or change the predictive ability of
MMP-3 and MMP-12. Also, we will analyze longitudinal samples
of serum on the same cohort to understand how chronicity of the
biomarkers impact disease development.
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